晚期软骨肉瘤的治疗靶点和新兴治疗方法。
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
机构信息
Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
出版信息
Int J Mol Sci. 2022 Jan 20;23(3):1096. doi: 10.3390/ijms23031096.
Abstract
Due to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including and . Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas.
摘要
由于对标准抗癌药物的耐药性，转移性或不可切除性软骨肉瘤患者的疾病进展难以控制。需要新的治疗方法，如分子靶向药物和免疫疗法，以改善晚期软骨肉瘤患者的临床结果。最近的研究表明，软骨肉瘤有几个有前途的生物标志物和治疗靶点，包括 和 。几种分子靶向药物和免疫疗法在晚期软骨肉瘤患者的临床研究中显示出良好的抗肿瘤活性。本综述总结了最近关于软骨肉瘤生物标志物和分子靶点的基础研究和最近关于软骨肉瘤治疗的临床研究。
相似文献
1
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Int J Mol Sci. 2022 Jan 20;23(3):1096. doi: 10.3390/ijms23031096.
2
Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Br J Cancer. 2018 Apr;118(8):1074-1083. doi: 10.1038/s41416-018-0050-9. Epub 2018 Mar 26.
3
The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Am Soc Clin Oncol Educ Book. 2015:e648-55. doi: 10.14694/EdBook_AM.2015.35.e648.
4
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment.
Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300.
5
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12.
6
[I. Identification of a Possible Therapeutic Target for Chondrosarcoma with IDH Mutant Inhibitors].
Gan To Kagaku Ryoho. 2017 Mar;44(3):212-216.
7
Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Arch Pathol Lab Med. 2021 Aug 1;145(8):1009-1017. doi: 10.5858/arpa.2020-0379-OA.
8
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Hum Pathol. 2017 Jul;65:239-246. doi: 10.1016/j.humpath.2017.05.015. Epub 2017 May 25.
9
Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets.
Crit Rev Oncol Hematol. 2018 Nov;131:102-109. doi: 10.1016/j.critrevonc.2018.09.001. Epub 2018 Sep 12.
10
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
Nat Genet. 2013 Aug;45(8):923-6. doi: 10.1038/ng.2668. Epub 2013 Jun 16.
引用本文的文献
1
Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma.
Front Mol Biosci. 2025 Jul 1;12:1591644. doi: 10.3389/fmolb.2025.1591644. eCollection 2025.
2
Exploring the causal relationship between immune factors and chondrosarcoma: a Mendelian randomization study.
Discov Oncol. 2025 May 18;16(1):801. doi: 10.1007/s12672-025-02654-5.
3
Causal effect of gut microbiota metabolic pathways on CSAG1 expression in chondrosarcoma: a mendelian randomization analysis.
BMC Cancer. 2025 May 9;25(1):852. doi: 10.1186/s12885-025-14281-y.
4
Maxillary aggressive chondrosarcoma: A rare and challenging case.
Radiol Case Rep. 2025 Mar 8;20(5):2521-2526. doi: 10.1016/j.radcr.2025.02.003. eCollection 2025 May.
5
Impact of the Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor in Conventional Chondrosarcoma.
Indian J Surg Oncol. 2025 Feb;16(1):356-363. doi: 10.1007/s13193-024-02100-y. Epub 2024 Sep 23.
6
DNA methyltransferase 3A: A prognostic biomarker and potential target for immunotherapy in gastric cancer.
Medicine (Baltimore). 2025 Feb 14;104(7):e41578. doi: 10.1097/MD.0000000000041578.
7
Research trends and foci in chondrosarcoma: A bibliometric and network analysis.
Medicine (Baltimore). 2024 Nov 8;103(45):e40403. doi: 10.1097/MD.0000000000040403.
8
RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7.
Cancer Metab. 2024 Oct 25;12(1):30. doi: 10.1186/s40170-024-00359-x.
9
Multiple enchondromas in Ollier's disease: A case report.
Radiol Case Rep. 2024 Aug 19;19(11):5033-5037. doi: 10.1016/j.radcr.2024.07.080. eCollection 2024 Nov.
10
Keratin 17 and Collagen type 1 genes: Esophageal cancer molecular marker discovery and evaluation.
Clin Respir J. 2024 Jul;18(7):e13793. doi: 10.1111/crj.13793.
本文引用的文献
1
Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.
Mol Oncol. 2022 Jun;16(11):2174-2194. doi: 10.1002/1878-0261.13160. Epub 2022 Jan 1.
2
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing's Sarcoma and Chondrosarcoma.
Cells. 2021 Oct 26;10(11):2893. doi: 10.3390/cells10112893.
3
The Key Gene Expression Patterns and Prognostic Factors in Malignant Transformation from Enchondroma to Chondrosarcoma.
Front Oncol. 2021 Sep 10;11:693034. doi: 10.3389/fonc.2021.693034. eCollection 2021.
4
Targeting of cancer cell death mechanisms by resveratrol: a review.
Apoptosis. 2021 Dec;26(11-12):561-573. doi: 10.1007/s10495-021-01689-7. Epub 2021 Sep 25.
5
Prognostic impact of IDH mutations in chondrosarcoma.
J Orthop Sci. 2022 Nov;27(6):1315-1322. doi: 10.1016/j.jos.2021.07.024. Epub 2021 Sep 14.
6
SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone.
Cancers (Basel). 2021 Jul 29;13(15):3823. doi: 10.3390/cancers13153823.
7
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Cancer Med. 2021 Jul;10(13):4415-4423. doi: 10.1002/cam4.4019. Epub 2021 Jun 3.
8
Chondrosarcoma-from Molecular Pathology to Novel Therapies.
Cancers (Basel). 2021 May 14;13(10):2390. doi: 10.3390/cancers13102390.
9
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence.
Cancers (Basel). 2021 May 17;13(10):2408. doi: 10.3390/cancers13102408.
10
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
Eur J Cancer. 2021 Jun;150:108-118. doi: 10.1016/j.ejca.2021.03.039. Epub 2021 Apr 22.
Zotero 插件